CDK7抑制剂联合方案对骨髓增殖性肿瘤转化为急性髓系白血病的临床前疗效
该临床前研究显示,CDK7抑制剂SY-5609可清除骨髓增殖性肿瘤转化急性髓系白血病(post-MPN sAML)的表型干/祖细胞,并在培养细胞中抑制生长、诱导死亡且不损伤正常细胞。SY-5609与芦可替尼、BET抑制剂OTX015或pelabresib、CBP/p300抑制剂GNE-049联用均呈协同致死作用;在HEL-Luc/GFP异种移植模型中,SY-5609联合OTX015较单药降低sAML负荷并改善生存且无宿主毒性。
要点
- CDK7抑制剂SY-5609在post-MPN sAML细胞中抑制生长并诱导死亡,同时不损伤正常细胞。
- SY-5609与芦可替尼、BET抑制剂或CBP/p300抑制剂联用对MPN-AML细胞呈协同致死作用。
- HEL-Luc/GFP异种移植模型中,SY-5609联合OTX015较单药降低sAML负荷、改善生存且无宿主毒性。
核心结论
- CDK7抑制剂为基础的联合方案(与BET抑制剂或CBP/p300抑制剂)对晚期MPN包括post-MPN sAML显示出有前景的临床前活性。
研究设计与样本
- 临床前研究:使用培养的post-MPN sAML细胞系SET2、HEL及患者来源的post-MPN sAML细胞,并进行HEL-Luc/GFP异种移植模型实验。
主要发现
- SY-5609处理培养的post-MPN sAML SET2、HEL和患者来源细胞可抑制生长并诱导死亡,同时不损伤正常细胞。
- SY-5609处理后RNA测序显示MYC、MYB、CDK4/6、PIM1和CCND1的mRNA表达降低,CDKN1A和BCL2L1表达升高。
- SY-5609处理MPN-AML细胞的质谱分析显示c-Myc、c-Myb、PIM1和CDK4/6蛋白降低,p21、caspase-9和BAD蛋白升高。
- CRISPR介导的CDK7敲低也降低HEL细胞活力;CyTOF分析显示SY-5609处理的患者来源post-MPN sAML干/祖细胞中c-Myc、CDK6和PU.1降低,CD11b、p21和cleaved caspase-3升高。
- 在HEL-Luc/GFP异种移植模型中,与各单药相比,SY-5609联合OTX015降低sAML负荷并改善生存,且无宿主毒性。
关键数值与推荐
- SY-5609与芦可替尼联用在HEL、SET2和患者来源post-MPN sAML细胞中呈协同致死作用。
- CRISPR筛选显示BRD4、CBP和p300为与CDK7抑制剂共依赖的靶点。
- SY-5609与BET抑制剂OTX015或pelabresib、或CBP/p300抑制剂GNE-049联用在MPN-AML细胞(包括TP53缺失者)中呈协同致死作用。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rising blast percentage or secondary acute myeloid leukemia (sAML) transformation in myeloproliferative neoplasms (MPNs) leads to JAK1/2 inhibitor (JAKi) therapy resistance and poor survival. Here, we demonstrate that treatment with the CDK7 inhibitor (CDK7i) SY-5609 depletes phenotypically characterized post-MPN sAML stem/progenitor cells. In cultured post-MPN sAML SET2, HEL and patient-derived (PD) post-MPN sAML cells, SY-5609 treatment inhibited growth and induced lethality while sparing normal cells. RNA-sequencing analysis after SY-5609 treatment reduced mRNA expression of MYC, MYB, CDK4/6, PIM1, and CCND1 but increased expression of CDKN1A and BCL2L1. Mass spectrometry of SY-5609-treated MPN-sAML cells also reduced c-Myc, c-Myb, PIM1, and CDK4/6 but increased p21, caspase-9, and BAD protein levels. CRISPR-mediated CDK7 depletion also reduced cell viability of HEL cells. Cytometry by time of flight (CyTOF) analysis of SY-5609-treated PD post-MPN sAML stem/progenitor cells showed reduced c-Myc, CDK6, and PU.1 but increased protein levels of CD11b, p21, and cleaved caspase-3. Cotreatment with SY-5609 and ruxolitinib was synergistically lethal in HEL, SET2, and PD post-MPN sAML cells. A CRISPR screen in sAML cells revealed BRD4, CBP, and p300 as codependencies with CDK7i. Accordingly, cotreatment with SY-5609 and the bromodomain and extra-terminal protein inhibitor (BETi) OTX015 or pelabresib or the CBP/p300 inhibitor GNE-049 was synergistically lethal in MPN-sAML cells (including those exhibiting TP53 loss). Finally, in the HEL-Luc/GFP xenograft model, compared with each agent alone, cotreatment with SY-5609 and OTX015 reduced sAML burden and improved survival without host toxicity. These findings demonstrate promising preclinical activity of CDK7i-based combinations with BETi or CBP/p300 inhibitor against advanced MPNs, including post-MPN sAML.
引用
- Fiskus W, Mill CP, Bose P, et al. Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML. Blood. 2025. PMID: 39561280. doi:10.1182/blood.2024026388
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。